Skip to main content
Top
Published in: Gastric Cancer 4/2020

Open Access 01-07-2020 | Neuroendocrine Tumor | Original Article

Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research

Authors: Ping Hu, Jian’an Bai, Min Liu, Jingwen Xue, Tiaotiao Chen, Rui Li, Xiaoling Kuai, Haijian Zhao, Xiaolin Li, Ye Tian, Wei Sun, Yujia Xiong, Qiyun Tang

Published in: Gastric Cancer | Issue 4/2020

Login to get access

Abstract

Background

To investigate the recent epidemiological trends of gastric neuroendocrine neoplasms (GNENs) and establish a new tool to estimate the prognosis of gastric neuroendocrine carcinoma (GNEC) and gastric neuroendocrine tumor (GNET).

Methods

Nomograms were established based on a retrospective study on patients diagnosed with GNENs from 1975 to 2016 in Surveillance, Epidemiology and End Results database. External validation was performed among 246 GNENs patients in Jiangsu province to verify the discrimination and calibration of the nomograms.

Results

The age-adjusted incidence of GNENs has increased from 0.309 to 6.149 per 1,000,000 persons in the past 4 decades. Multivariate analysis indicated independent prognostic factors for both GNEC and GNET including age, distant metastasis and surgical intervention (P < 0.05). In addition, T, N staging and grade were significantly associated with survival of GNEC, while size was a predictor for GNET (P < 0.05). The C-indexes of the nomograms were 0.840 for GNEC and 0.718 for GNET, which were higher than those of the 8th AJCC staging system (0.773 and 0.599). Excellent discrimination was observed in the validation cohorts (C-index of nomogram vs AJCC staging for GNEC: 0.743 vs 0.714; GNET: 0.945 vs 0.927). Survival rates predicted by nomograms were close to the actual survival rates in the calibration plots in both training and validation sets.

Conclusions

The incidence of the GNENs is increasing steadily in the past 40 years. We established more excellent nomograms to predict the prognosis of GNENs than traditional staging system, helping clinicians to make tailored decisions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.CrossRef Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.CrossRef
2.
go back to reference Yang Z, Wang WH, Lu JF, Pan GF, Pan ZY, Chen Q, et al. Gastric neuroendocrine tumors (G-Nets): incidence, prognosis and recent trend toward improved survival. Cell Physiol Biochem. 2018;45:389–96.CrossRef Yang Z, Wang WH, Lu JF, Pan GF, Pan ZY, Chen Q, et al. Gastric neuroendocrine tumors (G-Nets): incidence, prognosis and recent trend toward improved survival. Cell Physiol Biochem. 2018;45:389–96.CrossRef
3.
go back to reference Flejou JF. WHO classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31:S27–31.CrossRef Flejou JF. WHO classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31:S27–31.CrossRef
4.
go back to reference Xie JW, Lu J, Wang JB, Lin JX, Chen QY, Cao LL, et al. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients. BMC Cancer. 2018;18:1021.CrossRef Xie JW, Lu J, Wang JB, Lin JX, Chen QY, Cao LL, et al. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients. BMC Cancer. 2018;18:1021.CrossRef
5.
go back to reference Kim BS, Park YS, Yook JH, Kim BS. Comparison of relapse-free survival in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma. Ther Adv Gastroenterol. 2017;10:407–15.CrossRef Kim BS, Park YS, Yook JH, Kim BS. Comparison of relapse-free survival in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma. Ther Adv Gastroenterol. 2017;10:407–15.CrossRef
6.
go back to reference Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629–38.CrossRef Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629–38.CrossRef
7.
go back to reference Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018;124:807–15.CrossRef Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018;124:807–15.CrossRef
8.
go back to reference Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42:1464–70.CrossRef Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42:1464–70.CrossRef
9.
go back to reference Xie JW, Li P, Wang JB, Lin JX, Lu J, Chen QY, et al. Modified AJCC staging of gastric neuroendocrine carcinoma based on T staging can improve the capacity of prognosis assessment. J Cancer Res Clin Oncol. 2018;144:2391–7.CrossRef Xie JW, Li P, Wang JB, Lin JX, Lu J, Chen QY, et al. Modified AJCC staging of gastric neuroendocrine carcinoma based on T staging can improve the capacity of prognosis assessment. J Cancer Res Clin Oncol. 2018;144:2391–7.CrossRef
10.
go back to reference Zhong Q, Chen QY, Xie JW, Wang JB, Lin JX, Lu J, et al. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: a large population-based study. Cancer Med. 2018;7:3521–33.CrossRef Zhong Q, Chen QY, Xie JW, Wang JB, Lin JX, Lu J, et al. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: a large population-based study. Cancer Med. 2018;7:3521–33.CrossRef
11.
go back to reference Callahan AF, White M, Ituarte P, Gagandeep S, Woo Y, Fong Y, et al. Surgical intervention in gastric carcinoid is associated with improved survival in local and regional disease. Am J Clin Oncol. 2018;41:882–7.CrossRef Callahan AF, White M, Ituarte P, Gagandeep S, Woo Y, Fong Y, et al. Surgical intervention in gastric carcinoid is associated with improved survival in local and regional disease. Am J Clin Oncol. 2018;41:882–7.CrossRef
12.
go back to reference Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Chin J Cancer. 2017;36:51.CrossRef Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Chin J Cancer. 2017;36:51.CrossRef
13.
go back to reference Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.CrossRef Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.CrossRef
14.
go back to reference Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, et al. Incidence and survival trends for gastric neuroendocrine neoplasms: an analysis of 3523 patients in the SEER database. Eur J Surg Oncol. 2018;44:1628–33.CrossRef Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, et al. Incidence and survival trends for gastric neuroendocrine neoplasms: an analysis of 3523 patients in the SEER database. Eur J Surg Oncol. 2018;44:1628–33.CrossRef
15.
go back to reference Sorbye H, Baudin E, Perren A. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinol Metab Clin. 2018;47:683–98.CrossRef Sorbye H, Baudin E, Perren A. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinol Metab Clin. 2018;47:683–98.CrossRef
16.
go back to reference Vanoli A, La Rosa S, Miceli E, Klersy C, Maragliano R, Capuano F, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology. 2018;107:114–26.CrossRef Vanoli A, La Rosa S, Miceli E, Klersy C, Maragliano R, Capuano F, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology. 2018;107:114–26.CrossRef
17.
go back to reference Tian FX, Cai YQ, Zhuang LP, Chen MF, Xiu ZB, Zhang Y, et al. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: a population-based study. Cancer Med. 2018;7:5359–69.CrossRef Tian FX, Cai YQ, Zhuang LP, Chen MF, Xiu ZB, Zhang Y, et al. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: a population-based study. Cancer Med. 2018;7:5359–69.CrossRef
18.
go back to reference Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119–24.CrossRef Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119–24.CrossRef
19.
go back to reference Boyce M, Thomsen L. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol. 2015;50:550–9.CrossRef Boyce M, Thomsen L. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol. 2015;50:550–9.CrossRef
20.
go back to reference Sackstein PE, O’Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45:249–58.CrossRef Sackstein PE, O’Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45:249–58.CrossRef
21.
go back to reference Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, et al. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: an analysis of the U.S. Neuroendocrine Tumor Study Group. J Surg Oncol. 2018;117:868–78.CrossRef Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, et al. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: an analysis of the U.S. Neuroendocrine Tumor Study Group. J Surg Oncol. 2018;117:868–78.CrossRef
22.
go back to reference McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D. A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours. Can J Surg. 2017;60:192–7.CrossRef McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D. A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours. Can J Surg. 2017;60:192–7.CrossRef
Metadata
Title
Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research
Authors
Ping Hu
Jian’an Bai
Min Liu
Jingwen Xue
Tiaotiao Chen
Rui Li
Xiaoling Kuai
Haijian Zhao
Xiaolin Li
Ye Tian
Wei Sun
Yujia Xiong
Qiyun Tang
Publication date
01-07-2020
Publisher
Springer Singapore
Published in
Gastric Cancer / Issue 4/2020
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-020-01046-8

Other articles of this Issue 4/2020

Gastric Cancer 4/2020 Go to the issue